Engineered cocultures of iPSC-derived atrial cardiomyocytes and atrial fibroblasts for modeling atrial fibrillation.
Grace E BrownYong Duk HanAshlin R MichellOlivia T LyCarlos G VanoyeEmanuele SpangheroAlfred L GeorgeDawood DarbarSalman R KhetaniPublished in: Science advances (2024)
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia treatable with antiarrhythmic drugs; however, patient responses remain highly variable. Human induced pluripotent stem cell-derived atrial cardiomyocytes (iPSC-aCMs) are useful for discovering precision therapeutics, but current platforms yield phenotypically immature cells and are not easily scalable for high-throughput screening. Here, primary adult atrial, but not ventricular, fibroblasts induced greater functional iPSC-aCM maturation, partly through connexin-40 and ephrin-B1 signaling. We developed a protein patterning process within multiwell plates to engineer patterned iPSC-aCM and atrial fibroblast coculture (PC) that significantly enhanced iPSC-aCM structural, electrical, contractile, and metabolic maturation for 6+ weeks compared to conventional mono-/coculture. PC displayed greater sensitivity for detecting drug efficacy than monoculture and enabled the modeling and pharmacological or gene editing treatment of an AF-like electrophysiological phenotype due to a mutated sodium channel. Overall, PC is useful for elucidating cell signaling in the atria, drug screening, and modeling AF.
Keyphrases
- atrial fibrillation
- catheter ablation
- induced pluripotent stem cells
- left atrial
- high glucose
- left atrial appendage
- oral anticoagulants
- direct oral anticoagulants
- endothelial cells
- heart failure
- drug induced
- percutaneous coronary intervention
- diabetic rats
- induced apoptosis
- skeletal muscle
- single cell
- stem cells
- small molecule
- left ventricular
- bone marrow
- emergency department
- case report
- cell cycle arrest
- young adults
- adverse drug
- binding protein